Effects of the inhibition of intestinal P‐glycoprotein on aliskiren pharmacokinetics in cynomolgus monkeys
- 29 September 2014
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 36 (1) , 15-33
Abstract
Aliskiren is a substrate for P‐glycoprotein (P‐gp) and is metabolized via cytochrome P450 3A4 (CYP3A4). The aim of the present study was to assess whether P‐gp influenced the pharmacokinetics of aliskiren and also if drug–drug interactions (DDIs) mediated through P‐gp could be reproduced in cynomolgus monkeys. The study investigated the pharmacokinetics of aliskiren inmdr1a/1bgene‐deficient (P‐gp KO) and wild‐type (WT) mice. The area under the plasma concentration–time curve (AUC) following the oral administration of aliskiren was 6.9‐fold higher in P‐gp KO mice than in WT mice, while no significant differences were observed in theAUCor total plasma clearance following the intravenous administration of aliskiren to P‐gp KO mice. Then the pharmacokinetics of aliskiren were evaluated and DDIs between aliskiren and P‐gp inhibitors, such as cyclosporin A (CsA) and zosuquidar, examined in cynomolgus monkeys. TheAUCfor aliskiren were 8.3‐ and 42.1‐fold higher after the oral administration of aliskiren with the concomitant oral administration of zosuquidar and CsA at doses of 10 and 30 mg/kg, respectively. In contrast, theAUCafter the intravenous and oral administration of aliskiren was not significantly affected by the oral administration of zosuquidar or intravenous administration of CsA, respectively. These results indicated that P‐gp strictly limited the intestinal absorption of aliskiren in mice and monkeys, and also that the effects of intestinal P‐gp inhibition by CsA or zosuquidar on the pharmacokinetics of aliskiren were sensitively reproduced in monkeys. In conclusion, aliskiren can be used as a sensitive substrate to evaluate intestinal P‐gp inhibition in monkeys. Copyright © 2014 John Wiley & Sons, Ltd.Keywords
This publication has 33 references indexed in Scilit:
- Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskirenBritish Journal of Clinical Pharmacology, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Optimization of orally bioavailable alkyl amine renin inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- Cynomolgus monkey CYPs: a comparison with human CYPsXenobiotica, 2009
- Characterization of Gastrointestinal Drug Absorption in Cynomolgus MonkeysMolecular Pharmaceutics, 2008
- Clinical Pharmacokinetics and Pharmacodynamics of AliskirenClinical Pharmacokinetics, 2008
- Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P‐glycoproteinBritish Journal of Clinical Pharmacology, 2006
- Grapefruit Juice Reduces the Oral Bioavailability of Fexofenadine But Not DesloratadineClinical Pharmacokinetics, 2002
- Epithelial Transport Of Drugs In Cell Culture. I: A Model For Studying The Passive Diffusion Of Drugs Over Intestinal Absorbtive (Caco-2) CellsJournal of Pharmaceutical Sciences, 1990
- Clinical Pharmacokinetics of CyclosporinClinical Pharmacokinetics, 1986